Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update